Theralase Technologies Inc. V.TLT

Takeda, Hutchmed hook up on cancer drug for $1.13B

[ScienceFirst]

Valuation example.  By the way, HutchMed is the big pharma of Li Ka Shing's family.

Takeda, Hutchmed hook up on cancer drug for $1.13B

Takeda has gained commercial rights to Hutchmed's cancer drug fruquintinib outside of China for $400M up front, plus $730M in potential milestones.


The latest big pharma player to get a piece of the action however is closer to home. Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments.

[Rumpl3StiltSkin]

So TLT could do somethig similar? Just for 1433? or is it for just the one indication? Valuation wise...

[ScienceFirst]

Rump ... That was comparing valuations

[Rumpl3StiltSkin]

Ok, I was thinking TLT might make a similar deal for 1433, then keep the other Osmium/Iridium based PDCs to go after Brain, Lung, Breast, etc. Would certainly bring in a ton of money.

[Yajne]

Great dialog regarding TLT's potential on TLD 1433 for which I am extremely optimistic! However, can any of these possible deals be concluded during Q1 which would eliminate funding concern? Or maybe $400K/mo burn rate has dropped due to events that we're not aware of, deferred salaries or similar? ...which would have the effect of extending the timing. JMHO DYODD. Any expert thoughts

[ScienceFirst]

Discussions with big pharmas will take more time than being complered by Q1.  Wait time, back and forth, analysis, etc ....  I posted some examples 3-4 times.

[Rumpl3StiltSkin]

Yajne, I'm still thinking they have enough $$ to get to the BTD and possibly AA position that they 'should' be in by July... SP  'should' be much better then and so will all possible venues for funding. IF they need funds sooner they could just do another smallish PP, right?